Surmodics is a medical technology company with two core businesses: a performance coatings licensing business and a proprietary vascular intervention devices business. In the coatings business, Surmodics develops hydrophilic, drug-delivery, and hemocompatibility surface coatings for medical devices — such as the lubricious coatings that allow catheters and guidewires to navigate blood vessels — and licenses these technologies to device manufacturers including Abbott, Boston Scientific, Medtronic, and over 150 other product families. Customers pay royalties as a percentage of their own product sales, plus license and milestone fees, creating a capital-light, recurring revenue stream. In vascular intervention, Surmodics develops and sells its own devices: the SurVeil drug-coated balloon (DCB) for peripheral artery disease, which Surmodics manufactures and sells exclusively to Abbott for U.S. commercialization under a profit-sharing arrangement; the Pounce thrombectomy platform, a mechanical clot-removal system sold directly to hospitals; and the Sublime radial access portfolio, guide sheaths and catheters that enable peripheral artery treatment via wrist access, also sold directly. Surmodics also operates a smaller In Vitro Diagnostics segment, which sells components used by diagnostic companies to build immunoassay tests, and generates high-margin cash that helps fund the vascular intervention buildout. Surmodics is transitioning from a licensing-heavy model toward one where proprietary device sales represent a larger share of revenue.